183 related articles for article (PubMed ID: 10569749)
1. Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V.
Areschoug T; Stålhammar-Carlemalm M; Larsson C; Lindahl G
Infect Immun; 1999 Dec; 67(12):6350-7. PubMed ID: 10569749
[TBL] [Abstract][Full Text] [Related]
2. Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections.
Stålhammar-Carlemalm M; Stenberg L; Lindahl G
J Exp Med; 1993 Jun; 177(6):1593-603. PubMed ID: 8496678
[TBL] [Abstract][Full Text] [Related]
3. Cross-protection between group A and group B streptococci due to cross-reacting surface proteins.
Stâlhammar-Carlemalm M; Areschoug T; Larsson C; Lindahl G
J Infect Dis; 2000 Jul; 182(1):142-9. PubMed ID: 10882591
[TBL] [Abstract][Full Text] [Related]
4. A protective surface protein from type V group B streptococci shares N-terminal sequence homology with the alpha C protein.
Lachenauer CS; Madoff LC
Infect Immun; 1996 Oct; 64(10):4255-60. PubMed ID: 8926097
[TBL] [Abstract][Full Text] [Related]
5. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Infect Immun; 1996 Sep; 64(9):3518-23. PubMed ID: 8751893
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of group B protective surface protein, a new cell surface protective antigen of group B streptococci.
Erdogan S; Fagan PK; Talay SR; Rohde M; Ferrieri P; Flores AE; Guzmán CA; Walker MJ; Chhatwal GS
Infect Immun; 2002 Feb; 70(2):803-11. PubMed ID: 11796614
[TBL] [Abstract][Full Text] [Related]
7. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Vaccine; 1999 Feb; 17(5):454-8. PubMed ID: 10073723
[TBL] [Abstract][Full Text] [Related]
8. Putative novel surface-exposed Streptococcus agalactiae protein frequently expressed by the group B streptococcus from Zimbabwe.
Mavenyengwa RT; Maeland JA; Moyo SR
Clin Vaccine Immunol; 2009 Sep; 16(9):1302-8. PubMed ID: 19587152
[TBL] [Abstract][Full Text] [Related]
9. Immunological markers of the R4 protein of Streptococcus agalactiae.
Maeland JA; Bevanger L; Lyng RV
Clin Diagn Lab Immunol; 2005 Nov; 12(11):1305-10. PubMed ID: 16275945
[TBL] [Abstract][Full Text] [Related]
10. Temperature-Induced Self-Assembly of the Group B Streptococcus (GBS) Fusion Antigen GBS-NN.
Rose F; Roovers S; Fano M; Harloff-Helleberg S; Kirkensgaard JJK; Hejnaes K; Fischer P; Foged C
Mol Pharm; 2018 Jul; 15(7):2584-2593. PubMed ID: 29745668
[TBL] [Abstract][Full Text] [Related]
11. Analysis of recombinant group B streptococcal protein ScaAB and evaluation of its immunogenicity.
Vorobieva EI; Meringova LF; Leontieva GF; Grabovskaya KB; Suvorov AN
Folia Microbiol (Praha); 2005; 50(2):172-6. PubMed ID: 16110924
[TBL] [Abstract][Full Text] [Related]
12. A unique serine-rich repeat protein (Srr-2) and novel surface antigen (epsilon) associated with a virulent lineage of serotype III Streptococcus agalactiae.
Seifert KN; Adderson EE; Whiting AA; Bohnsack JF; Crowley PJ; Brady LJ
Microbiology (Reading); 2006 Apr; 152(Pt 4):1029-1040. PubMed ID: 16549667
[TBL] [Abstract][Full Text] [Related]
13. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
[TBL] [Abstract][Full Text] [Related]
14. Molecular epidemiology and distribution of serotypes, surface proteins, and antibiotic resistance among group B streptococci in Italy.
Gherardi G; Imperi M; Baldassarri L; Pataracchia M; Alfarone G; Recchia S; Orefici G; Dicuonzo G; Creti R
J Clin Microbiol; 2007 Sep; 45(9):2909-16. PubMed ID: 17634303
[TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.
Larsson C; Holmgren J; Lindahl G; Bergquist C
Infect Immun; 2004 Feb; 72(2):1184-7. PubMed ID: 14742572
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.
Seepersaud R; Hanniffy SB; Mayne P; Sizer P; Le Page R; Wells JM
Infect Immun; 2005 Mar; 73(3):1671-83. PubMed ID: 15731068
[TBL] [Abstract][Full Text] [Related]
17. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity.
Brodeur BR; Boyer M; Charlebois I; Hamel J; Couture F; Rioux CR; Martin D
Infect Immun; 2000 Oct; 68(10):5610-8. PubMed ID: 10992461
[TBL] [Abstract][Full Text] [Related]
18. Identification of a family of streptococcal surface proteins with extremely repetitive structure.
Wästfelt M; Stâlhammar-Carlemalm M; Delisse AM; Cabezon T; Lindahl G
J Biol Chem; 1996 Aug; 271(31):18892-7. PubMed ID: 8702550
[TBL] [Abstract][Full Text] [Related]
19. Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein.
Martin D; Rioux S; Gagnon E; Boyer M; Hamel J; Charland N; Brodeur BR
Infect Immun; 2002 Sep; 70(9):4897-901. PubMed ID: 12183534
[TBL] [Abstract][Full Text] [Related]
20. Nonimmunodominant regions are effective as building blocks in a streptococcal fusion protein vaccine.
Stålhammar-Carlemalm M; Waldemarsson J; Johnsson E; Areschoug T; Lindahl G
Cell Host Microbe; 2007 Dec; 2(6):427-34. PubMed ID: 18078694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
